Platinum compounds iproplatin

Figure 3.116 Platinum compounds studied for possible anti-tumour activity. I, ris-Dichlorodi-ammineplatinum(II) cisplatin, platinol NSC 119875 neoplatin platinex. II, a.s-Diammine(l,l-cyclobutanedicarboxylato)platinum(II) JM-8 paraplatin NSC 241240. Ill, Oxiplatin. IV, Tetraplatin. V, Amminediacetatodichloro(cyclohexylamine)platinum(IV). VI, cis-Dich oro-trans-dihydroxy-cis-bis(isopropylamine)platinum(IV) iproplatin JM-19 CHIP NSC 256927.

Platinum (IV) Structures. The oxidation state of the platinum atom in platinum coordination compounds determines the steric configuration of the molecule platinum(II) structures are planar molecules, while platinum(IV) derivatives assume an octahedral shape. Though it was hoped that these differences could be used to circumvent platinum resistance, the two compounds developed in the clinic, iproplatin and ormaplatin, have not proven useful. In the case of the former, testing in Phase-II trials failed to reveal activity. In the case of ormaplatin, the platinum(IV) configuration is not maintained under biological conditions conversion to a platinum(II) metabolite occurs within minutes [14], A series of novel platinum(IV) and mixed ammine/amine derivatives being developed at the Institute for Cancer Research are described in this volume by Kelland. 

---